WO2013181217A3 - Novel compounds and compositions for treatment of breathing control disorders or diseases - Google Patents

Novel compounds and compositions for treatment of breathing control disorders or diseases Download PDF

Info

Publication number
WO2013181217A3
WO2013181217A3 PCT/US2013/043052 US2013043052W WO2013181217A3 WO 2013181217 A3 WO2013181217 A3 WO 2013181217A3 US 2013043052 W US2013043052 W US 2013043052W WO 2013181217 A3 WO2013181217 A3 WO 2013181217A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
treatment
compositions
diseases
novel compounds
Prior art date
Application number
PCT/US2013/043052
Other languages
French (fr)
Other versions
WO2013181217A2 (en
Inventor
James C. Mannion
Scott L. Dax
Duncan Euan MACINTYRE
Francis John GOLDER
James Francis MCLEOD
Original Assignee
Galleon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/482,837 external-priority patent/US20120295911A1/en
Priority to AU2013267570A priority Critical patent/AU2013267570A1/en
Priority to CN201380040132.0A priority patent/CN104602694A/en
Priority to BR112014029703A priority patent/BR112014029703A2/en
Priority to CA2875012A priority patent/CA2875012A1/en
Priority to EP13798039.7A priority patent/EP2855438A4/en
Application filed by Galleon Pharmaceuticals, Inc. filed Critical Galleon Pharmaceuticals, Inc.
Priority to KR20147036621A priority patent/KR20150020616A/en
Priority to SG11201407964YA priority patent/SG11201407964YA/en
Priority to JP2015515140A priority patent/JP2015521201A/en
Publication of WO2013181217A2 publication Critical patent/WO2013181217A2/en
Publication of WO2013181217A3 publication Critical patent/WO2013181217A3/en
Priority to HK15109840.6A priority patent/HK1209118A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.
PCT/US2013/043052 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases WO2013181217A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2015515140A JP2015521201A (en) 2012-05-29 2013-05-29 Novel compounds and compositions for the treatment of respiratory control disorders or respiratory control disorders
CN201380040132.0A CN104602694A (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases
BR112014029703A BR112014029703A2 (en) 2012-05-29 2013-05-29 composition, methods for preventing or treating a disorder or disease, for preventing destabilization or stabilization of respiration rate, for reducing or minimizing the open channel fraction of the maxi-k or bk potassium channel, to inhibit the task-1 channel, and to increase minute ventilation in a patient, crystalline free base, and, salt
CA2875012A CA2875012A1 (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases
EP13798039.7A EP2855438A4 (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases
AU2013267570A AU2013267570A1 (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases
KR20147036621A KR20150020616A (en) 2012-05-29 2013-05-29 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
SG11201407964YA SG11201407964YA (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases
HK15109840.6A HK1209118A1 (en) 2012-05-29 2015-10-08 Novel compounds and compositions for treatment of breathing control disorders or diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/482,837 2012-05-29
US13/482,837 US20120295911A1 (en) 2010-11-29 2012-05-29 Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases

Publications (2)

Publication Number Publication Date
WO2013181217A2 WO2013181217A2 (en) 2013-12-05
WO2013181217A3 true WO2013181217A3 (en) 2014-02-06

Family

ID=49674035

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/043052 WO2013181217A2 (en) 2012-05-29 2013-05-29 Novel compounds and compositions for treatment of breathing control disorders or diseases

Country Status (10)

Country Link
EP (1) EP2855438A4 (en)
JP (1) JP2015521201A (en)
KR (1) KR20150020616A (en)
CN (1) CN104602694A (en)
AU (1) AU2013267570A1 (en)
BR (1) BR112014029703A2 (en)
CA (1) CA2875012A1 (en)
HK (1) HK1209118A1 (en)
SG (1) SG11201407964YA (en)
WO (1) WO2013181217A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926816A (en) * 2014-03-19 2015-09-23 江苏先声药物研究有限公司 Tofacitinib analog and preparation method and application thereof
FR3076751B1 (en) * 2018-01-18 2020-10-23 Lebronze Alloys WELDING ELECTRODE FOR ALUMINUM OR STEEL SHEETS AND PROCESS FOR OBTAINING THE ELECTRODE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269832A (en) * 1978-04-12 1981-05-26 American Cyanamid Company Method of treating arthritic disease
US4642344A (en) * 1984-01-19 1987-02-10 Bayer Aktiengesellschaft Polyamines
US20050124619A1 (en) * 2001-09-21 2005-06-09 Timmer Richard T. Medical devices employing triazine compounds and compositions thereof
CN101885707A (en) * 2009-05-15 2010-11-17 中国科学院化学研究所 Triazine derivative and preparation method thereof as well as new application as insecticide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5661148A (en) * 1989-09-19 1997-08-26 Teijin Limited Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient
SG190921A1 (en) * 2010-11-29 2013-07-31 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) * 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CA2891342A1 (en) * 2012-11-15 2014-05-22 Galleon Pharmaceuticals, Inc. Novel orally bioavailable breathing control modulating compounds, and methods of using same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269832A (en) * 1978-04-12 1981-05-26 American Cyanamid Company Method of treating arthritic disease
US4642344A (en) * 1984-01-19 1987-02-10 Bayer Aktiengesellschaft Polyamines
US20050124619A1 (en) * 2001-09-21 2005-06-09 Timmer Richard T. Medical devices employing triazine compounds and compositions thereof
CN101885707A (en) * 2009-05-15 2010-11-17 中国科学院化学研究所 Triazine derivative and preparation method thereof as well as new application as insecticide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2855438A4 *

Also Published As

Publication number Publication date
HK1209118A1 (en) 2016-03-24
KR20150020616A (en) 2015-02-26
CN104602694A (en) 2015-05-06
JP2015521201A (en) 2015-07-27
WO2013181217A2 (en) 2013-12-05
CA2875012A1 (en) 2013-12-05
EP2855438A4 (en) 2016-02-24
SG11201407964YA (en) 2014-12-30
AU2013267570A1 (en) 2014-12-18
EP2855438A2 (en) 2015-04-08
BR112014029703A2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
WO2014078575A3 (en) Novel orally bioavailable breathing control modulating compounds, and methods of using same
MX2022004103A (en) An inhalable rapamycin formulation for treating age-related conditions.
BR112015022197A8 (en) use of a compound for the manufacture of a medicament or pharmaceutical composition for treating cataplexy
IN2015DN03219A (en)
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
WO2014052935A3 (en) Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease
EA033113B1 (en) Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
WO2012170918A3 (en) Methods of treatment for retinal diseases
WO2012142615A3 (en) Auranofin and auranofin analogs useful to treat proliferative disease and disorders
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
WO2013085849A3 (en) Sulfate esters of noribogaine
MX2018006247A (en) Methods for treating alzheimer's disease and related disorders.
AU2018253538A1 (en) Levodopa formulations for rapid relief of parkinson's disease
MX2014014066A (en) Chromane compounds.
MX357556B (en) Aqueous compositions comprising arbekacin.
MX2015016418A (en) Dihydroetorphine for the provision of pain relief and anaesthesia.
WO2014100679A8 (en) Stimulation and enhancement of regeneration of tissues
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
MX2015013137A (en) Novel breathing control modulating compounds, and methods of using same.
WO2014159917A3 (en) Treatment for exposure to nerve agent
BR112015007095A8 (en) dihydro-6-azafenalene derivatives for the treatment of snc, oncological diseases and related disorders, pharmaceutical composition comprising them and use of said derivatives
BR112014032264A8 (en) Composition for the treatment or prevention of diseases related to vascular permeability, containing imatinib or a pharmaceutically acceptable salt thereof as an active ingredient
WO2013038200A3 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13798039

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2875012

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2015515140

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2013267570

Country of ref document: AU

Date of ref document: 20130529

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20147036621

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2013798039

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013798039

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13798039

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014029703

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 112014029703

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20141127